Phase II Trial O6-benzylguanine(BG) and Temozolomide(TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140K MGMT+Hematopoietic Progenitors to Protect Hematopoiesis
This study is testing a new way to treat aggressive brain tumors called glioblastoma. Researchers are trying to see if protecting your bone marrow with a special gene therapy will allow doctors to use stronger doses of chemotherapy to better fight the cancer.
This trial is for adults between 18 and 75 who have recently had surgery to remove a specific type of brain tumor. You must be in generally good physical health and have a tumor with a specific genetic makeup known as 'unmethylated MGMT'.
You will receive a combination of chemotherapy drugs designed to stop tumor growth, along with a special gene therapy that helps your bone marrow withstand those stronger doses. The treatment process involves monitoring how your body responds to the medicine and ensuring your blood cells stay healthy.
The study is currently recruiting patients and is located in Cleveland, Ohio. You can discuss with your doctor whether this location works for your personal situation.
- 1Uses gene therapy to protect your bone marrow during intensive chemotherapy.
- 2Specifically designed for patients whose brain tumor has a 'unmethylated MGMT' genetic profile.
- 3Aims to safely increase the intensity of cancer treatment to better target tumor cells.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.